[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595983":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":12,"locations":25,"responsibleParty":38,"collaborators":12,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":12,"enrollmentInfo":52,"targetDuration":12,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":72,"whyStopped":12,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Sao Paulo","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group (CTRL)","NO_INTERVENTION","Participants will undergo health exams at specific time points: T0 (before the start of the anabolic-androgenic steroids cycle), T0.5 (4 weeks into the cycle), and T1 (8 weeks into the cycle) and T2 (one year after T1).",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Harm reduction group (HR)","EXPERIMENTAL","Participants will undergo health exams and complete the research questionnaires at time points T0, T0.5, T1 and T2. Additionally, every 15 days between T0 and T1, the harm reduction intervention will attend 30 minutes long counseling sessions with the research team. These brief counseling sessions are based on a technique known as \"Brief Intervention\", which focuses on the participant's needs and discussion of health exams results.",[18],"Behavioral: harm reduction intervention in non-clinical anabolic-androgenic steroids users",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"BEHAVIORAL","harm reduction intervention in non-clinical anabolic-androgenic steroids users","Participants will receive four structured counseling sessions, each lasting up to 30 minutes. Utilizing a non-judgmental harm reduction framework, these sessions aim to reduce substance abuse and address associated health risks. The intervention is person-centered, tailoring discussions to the user's specific needs and questions regarding their health and the use of non-clinical anabolic-androgenic steroids (AAS).",[14],[26],{"facility":27,"status":12,"city":28,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":12},"Clinical Hospital of the School of Medicine, University of Sao Paulo","São Paulo","05403-000","Brazil","BR",{"type":33,"coordinates":34},"Point",[35,36],-46.63611,-23.5475,{"lat":36,"lon":35},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Bruno Gualano","President of the Center for Lifestyle Medicine - School of Medicine of University of São Paulo","100595983","harm-reduction-intervention-for-anabolic-androgenic-steroids-users-a-randomized-controlled-trial-100595983",false,"NCT07039539","Harm Reduction Intervention for Anabolic-androgenic Steroids Users: a Randomized Controlled Trial","SOS-RCT-HR","Inclusion Criteria:\n\n* Anyone over 15 years of age;\n* Planning to use\u002Fincrease the dose of AAS for aesthetic and\u002For physical performance purposes;\n* Plan to use\u002Fincrease the dose of AAS during eight to twelve weeks.\n\nExclusion Criteria:\n\n* Medical prescription for AAS use;\n* Use for sexual reassignment.",true,"ALL","15 Years",{"count":53,"type":54},32,"ESTIMATED","INTERVENTIONAL",[57],"NA","This clinical trial aims to investigate the short and long-term efficacy of a harm reduction intervention in reducing the use of non-clinical anabolic-androgenic steroids (AAS) in abusive users of AAS. As secondary objectives, the study will investigate the intervention's effect on health parameters (i.e., blood), quality of life, sleep quality, body image, eating behavior, depression, anxiety, fatigue, aggressiveness, cardiovascular parameters, muscle strength, body composition and muscle cross-sectional area outcomes.",[60,61,62,63,64],"Drug Abuse","Harm Reduction","Minimization, Harm","Anabolic Steroids Adverse Events","Brief Intervention",[66,67,68,69,70,71,64],"human enhancement drug","performance and image enhancement drug","anabolic androgenic steroids","drug consumption","doping","harm reduction","NOT_YET_RECRUITING","2026-05-12",{"date":75,"type":76},"2026-05-18","ACTUAL",{"date":78,"type":54},"2026-07-01",{"date":80,"type":54},"2027-12-30",{"name":5,"class":6},1]